Company Performance - Bristol Myers Squibb (BMY) closed at $49, reflecting a +1.22% increase from the previous day, outperforming the S&P 500's daily gain of 0.09% [1] - The stock has risen by 4.22% over the past month, compared to a 2.17% gain in the Medical sector and a 7.21% gain in the S&P 500 [1] Upcoming Financial Results - The company is expected to report an EPS of $1.67, indicating a 19.32% decline year-over-year [2] - Projected revenue for the upcoming quarter is $11.32 billion, reflecting a 7.19% decrease compared to the same quarter last year [2] Annual Estimates - For the annual period, earnings are anticipated to be $6.85 per share, representing a +495.65% change from the previous year, while revenue is projected at $46.31 billion, indicating a -4.11% change [3] Analyst Forecasts - Recent revisions to analyst forecasts for Bristol Myers Squibb should be monitored, as they often reflect changes in short-term business dynamics [4] - Positive estimate revisions are seen as a sign of optimism regarding the company's business outlook [4] Zacks Rank and Valuation - The Zacks Rank system currently rates Bristol Myers Squibb at 3 (Hold), with a recent 0.57% decline in the Zacks Consensus EPS estimate [6] - The company is trading at a Forward P/E ratio of 7.06, significantly lower than the industry average of 19.71, suggesting it is trading at a discount [7] PEG Ratio and Industry Ranking - Bristol Myers Squibb has a PEG ratio of 1.41, close to the industry average of 1.43 [8] - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 78, placing it in the top 32% of over 250 industries [8][9]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD) . Shares have added about 26.1% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Th ...

Core Points - Spectral Medical Inc. held its Annual Meeting of shareholders on June 5, 2025, where all resolutions in the Management Information Circular were approved [1][2] Group 1: Election of Directors - Seven director nominees were elected with high approval rates, including Jan D'Alvise (99.78%), Jun Hayakawa (99.79%), and David W. Feigal, Jr. (99.67%) [3] Group 2: Appointment of Auditors - MNP LLP was re-appointed as the auditor of Spectral with 99.95% votes in favor [4] Group 3: Company Overview - Spectral is a Phase 3 company seeking U.S. FDA approval for its product Toraymyxin™ (PMX), a therapeutic hemoperfusion device for treating septic shock [4][5] - PMX has been approved for use in Japan and Europe, with over 360,000 applications to date [5] - The U.S. FDA granted Breakthrough Device Designation for PMX in July 2022 for endotoxic septic shock treatment [5] Group 4: Clinical Trials - The Tigris Trial is a confirmatory study comparing PMX in addition to standard care versus standard care alone, designed as a 2:1 randomized trial of 150 patients [6]

Mr. Chin brings over 20 years of financial experience across public and private healthcare organizationsMr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financingMr. Chin’s appointment strengthens Biomerica’s corporate governance and financial oversight as Biomerica scales commercialization efforts IRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company that develops, patents, manufactures and mark ...

Core Viewpoint - Denali Therapeutics Inc. has seen a slight increase in share price of about 0.7% over the past month, underperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Group 1: Earnings and Estimates - Estimates for Denali Therapeutics have trended upward over the past month, indicating positive revisions [2] - The stock has a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4] Group 2: VGM Scores - Denali Therapeutics has a poor Growth Score of F, a Momentum Score of C, and a Value Score of F, resulting in an overall aggregate VGM Score of F, placing it in the lowest quintile for investment strategies [3] Group 3: Industry Comparison - Denali Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where Moderna has experienced a gain of 13.3% over the past month [5] - Moderna reported revenues of $108 million for the last quarter, reflecting a year-over-year decline of 35.3%, with an EPS of -$2.52 compared to -$3.07 a year ago [5] - Moderna is projected to post a loss of $2.97 per share for the current quarter, with a year-over-year change of +10.8% and a Zacks Rank of 3 (Hold) [6]

Company Overview - Jazz Pharmaceuticals (JAZZ) shares have increased by approximately 7.9% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Estimates for Jazz Pharmaceuticals have trended downward, with a consensus estimate shift of -213.47% over the past month [2] - The overall trend indicates a negative outlook for the stock's performance [4] VGM Scores - Jazz Pharmaceuticals has a Growth Score of B, but a low Momentum Score of F, while maintaining a Value Score of B, placing it in the top 40% for value investment strategy [3] - The aggregate VGM Score for the stock is B, which is significant for investors not focused on a single strategy [3] Industry Performance - Jazz operates within the Zacks Medical - Biomedical and Genetics industry, where another player, Alkermes (ALKS), has seen a 3.8% gain over the past month [5] - Alkermes reported revenues of $306.51 million for the last quarter, reflecting a year-over-year decline of -12.5% [5] - Alkermes is expected to post earnings of $0.43 per share for the current quarter, indicating a year-over-year change of -40.3% [6]

Company Overview - Ultragenyx has seen its shares increase by approximately 9.6% over the past month, outperforming the S&P 500 [1] - The stock currently holds a Zacks Rank of 3 (Hold), indicating an expectation of an in-line return in the coming months [4] Earnings Estimates - Fresh estimates for Ultragenyx have trended upward in the past month, although the magnitude of these revisions suggests a downward shift [2][4] - The company has a subpar Growth Score of D, a strong Momentum Score of A, and a poor Value Score of F, placing it in the bottom 20% for value investment strategy [3] Industry Performance - Ultragenyx is part of the Zacks Medical - Biomedical and Genetics industry, where Agios Pharmaceuticals has gained 20.6% over the past month [5] - Agios Pharmaceuticals reported revenues of $8.73 million for the last quarter, reflecting a year-over-year increase of 6.6% [6] - The expected loss per share for Agios Pharmaceuticals in the current quarter is projected at $1.74, which is a 3% decrease year-over-year [6]

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps investors identify effective metrics for assessing momentum in stocks [2] Group 2: Instil Bio, Inc. (TIL) Performance - Instil Bio, Inc. currently holds a Momentum Style Score of A and a Zacks Rank of 2 (Buy), indicating strong potential for outperformance [3][4] - Over the past week, TIL shares have increased by 28.21%, significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by only 0.25% [6] - In a longer timeframe, TIL shares have gained 72.33% over the past quarter and 180.49% over the last year, while the S&P 500 has only moved 2.37% and 14.4%, respectively [7] Group 3: Trading Volume and Earnings Outlook - TIL's average 20-day trading volume is 383,563 shares, which is a bullish indicator when combined with rising stock prices [8] - Recent earnings estimate revisions for TIL show one upward revision for the full year, increasing the consensus estimate from -$8.30 to -$7.71 over the past 60 days [10] - For the next fiscal year, there has been one upward revision with no downward changes, indicating a positive earnings outlook [10] Group 4: Conclusion - Considering all performance metrics and earnings outlook, TIL is positioned as a strong buy candidate with a Momentum Score of A, making it a noteworthy option for investors seeking short-term gains [12]